Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. (APLS) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · APLS · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
45
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Apellis Pharmaceuticals, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
APLS insider buying and selling by quarter
APLS insider selling · APLS insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · APLS ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
APLS executive sell shares · APLS board member insider trading · APLS insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 14, 2026 | Dunlop A. Sinclair Director | Other | 3,544 | — | Form 4 |
| May 14, 2026 | Dunlop A. Sinclair Director | Other | 161,567 | $646K | Form 4 |
| May 14, 2026 | Chopas James George VP/Chief Accounting Officer | Award | 16,150 | — | Form 4 |
| May 14, 2026 | Chopas James George VP/Chief Accounting Officer | Award | 8,394 | — | Form 4 |
| May 14, 2026 | Chopas James George VP/Chief Accounting Officer | Award | 8,075 | — | Form 4 |
| May 14, 2026 | Chopas James George VP/Chief Accounting Officer | Award | 5,625 | — | Form 4 |
| May 14, 2026 | Chopas James George VP/Chief Accounting Officer | Other | 65,955 | $7 | Form 4 |
| May 14, 2026 | Chopas James George VP/Chief Accounting Officer | Other | 6,250 | — | Form 4 |
| May 14, 2026 | Dolsten Mikael Director | Other | 14,312 | — | Form 4 |
| May 14, 2026 | Dolsten Mikael Director | Other | 14,312 | $57K | Form 4 |
| May 14, 2026 | MELTZER LESLIE Chief Research and Development | Award | 45,220 | — | Form 4 |
| May 14, 2026 | MELTZER LESLIE Chief Research and Development | Award | 22,610 | — | Form 4 |
| May 14, 2026 | MELTZER LESLIE Chief Research and Development | Other | 45,220 | — | Form 4 |
| May 14, 2026 | MELTZER LESLIE Chief Research and Development | Other | 107,024 | $428K | Form 4 |
| May 14, 2026 | FONTEYNE PAUL R. Director | Other | 30,666 | $123K | Form 4 |
| May 14, 2026 | FONTEYNE PAUL R. Director | Other | 3,877 | — | Form 4 |
| May 14, 2026 | Sullivan Timothy Eugene CFO | Award | 58,140 | — | Form 4 |
| May 14, 2026 | Sullivan Timothy Eugene CFO | Award | 41,250 | — | Form 4 |
| May 14, 2026 | Sullivan Timothy Eugene CFO | Award | 30,620 | — | Form 4 |
| May 14, 2026 | Sullivan Timothy Eugene CFO | Award | 29,070 | — | Form 4 |
| May 14, 2026 | Sullivan Timothy Eugene CFO | Other | 71,492 | $286K | Form 4 |
| May 14, 2026 | Sullivan Timothy Eugene CFO | Other | 58,140 | — | Form 4 |
| May 14, 2026 | Machiels Alec Director | Other | 150,000 | $15 | Form 4 |
| May 14, 2026 | Machiels Alec Director | Other | 3,544 | — | Form 4 |
| May 14, 2026 | Deschatelets Pascal Chief Scientific Officer | Award | 41,250 | — | Form 4 |
Chopas James George
VP/Chief Accounting Officer
Date
May 14
Shares
16,150
Price
—
Value
—
Chopas James George
VP/Chief Accounting Officer
Date
May 14
Shares
8,394
Price
—
Value
—
Chopas James George
VP/Chief Accounting Officer
Date
May 14
Shares
8,075
Price
—
Value
—
Chopas James George
VP/Chief Accounting Officer
Date
May 14
Shares
5,625
Price
—
Value
—
Chopas James George
VP/Chief Accounting Officer
Date
May 14
Shares
65,955
Price
$0.00
Value
$7
Chopas James George
VP/Chief Accounting Officer
Date
May 14
Shares
6,250
Price
—
Value
—
MELTZER LESLIE
Chief Research and Development
Date
May 14
Shares
45,220
Price
—
Value
—
MELTZER LESLIE
Chief Research and Development
Date
May 14
Shares
22,610
Price
—
Value
—
MELTZER LESLIE
Chief Research and Development
Date
May 14
Shares
45,220
Price
—
Value
—
MELTZER LESLIE
Chief Research and Development
Date
May 14
Shares
107,024
Price
$4.00
Value
$428K
Deschatelets Pascal
Chief Scientific Officer
Date
May 14
Shares
41,250
Price
—
Value
—
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About APLS insider trading
APLS insider trades
Apellis Pharmaceuticals, Inc. (APLS) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Chopas James George (VP/Chief Accounting Officer), Sullivan Timothy Eugene (CFO), Deschatelets Pascal (Chief Scientific Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. APLS insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Apellis Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
APLS insider trading · 5 questionsThe insiders of Apellis Pharmaceuticals, Inc. (APLS) include executives and directors such as Chopas James George (VP/Chief Accounting Officer), Sullivan Timothy Eugene (CFO), Deschatelets Pascal (Chief Scientific Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026